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Abstract
Background: The randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial evaluated the JAK1/JAK2
inhibitor ruxolitinib in patients with intermediate-2/high-risk myelofibrosis. The primary and planned 3-year analyses
of COMFORT-I data demonstrated that ruxolitinib—the first myelofibrosis-approved therapy—reduced splenomegaly
and prolonged overall survival versus placebo. Here, we present the final 5-year results.
Methods: Patients managed in Australia, Canada, and the USA were randomized centrally (interactive voice response
system) 1:1 to oral ruxolitinib twice daily (15 or 20 mg per baseline platelet counts) or placebo. Investigators and
patients were blinded to treatment. The secondary endpoints evaluated in this analysis were durability of a ≥35%
reduction from baseline in spleen volume (spleen response) and overall survival, evaluated in the intent-to-treat
population. Safety was evaluated in patients who received study treatment.
Results: Patients were randomized (September 2009–April 2010) to ruxolitinib (n = 155) or placebo (n = 154). At
termination, 27.7% of ruxolitinib-randomized patients and 25.2% (28/111) who crossed over from placebo were
on treatment; no patients remained on placebo. Patients randomized to ruxolitinib had a median spleen
response duration of 168.3 weeks and prolonged median overall survival versus placebo (ruxolitinib group, not
reached; placebo group, 200 weeks; HR, 0.69; 95% CI, 0.50–0.96; P = 0.025) despite the crossover to ruxolitinib.
The ruxolitinib safety profile remained consistent with previous analyses. The most common new-onset all-grade
nonhematologic adverse events starting <12 versus ≥48 months after ruxolitinib initiation were fatigue (29.0 vs
33.3%) and diarrhea (27.8 vs 14.6%). New-onset grade 3 or 4 anemia and thrombocytopenia both primarily
occurred within the first 6 months, with no cases after 42 months. The most common treatment-emergent
adverse event-related deaths in the ruxolitinib-randomized group were sepsis (2.6%), disease progression (1.9%),
and pneumonia (1.9%).
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Conclusion: The final COMFORT-I results continue to support ruxolitinib as an effective treatment for patients
with intermediate-2/high-risk MF.
Trial registration: ClinicalTrials.gov, NCT00952289
Keywords: JAK, Janus kinase, Myelofibrosis
Background
Myelofibrosis (MF) is a Philadelphia chromosome-
negative myeloproliferative neoplasm [1] that is often as-
sociated with splenomegaly, anemia, and burdensome
symptoms that negatively affect quality of life [2, 3]. In
addition, patients with MF have shortened survival com-
pared with age- and sex-matched members of the gen-
eral population [4]. Allogeneic stem cell transplantation
is the only potentially curative treatment option [5].
However, transplant-related morbidity and mortality are
considerable, and many patients with MF are ineligible
because of their age or comorbidities.
Many patients with MF have mutations associated
with dysregulation of the Janus kinase (JAK)/signal
transducer and activator of transcription pathway. The
most common mutations are in JAK2 (55–65%), CALR
(15–25%), and MPL (5–15%); a relatively small subset of
patients is triple negative for mutations in all three genes
(10–20%) [6–9].
Ruxolitinib is a JAK1/JAK2 inhibitor approved by the
US Food and Drug Administration for patients with
intermediate- or high-risk MF, including primary MF
(PMF), post-polycythemia vera MF (PPV-MF), and post-
essential thrombocythemia MF (PET-MF), as well as pa-
tients with PV who have had an inadequate response to
or are intolerant of hydroxyurea [10]. Ruxolitinib is also
approved by the European Medicines Agency for the
treatment of disease-related splenomegaly or symptoms
in adult patients with PMF, PPV-MF, or PET-MF and for
the treatment of adult patients with PV who are resistant
to or intolerant of hydroxyurea [11]. Approval for MF
was based on two randomized phase 3 clinical trials in
patients with intermediate-2 or high-risk PMF, PPV-MF,
or PET-MF [12, 13]. Controlled Myelofibrosis Study with
Oral JAK Inhibitor Treatment (COMFORT)-I was a
double-blind, placebo-controlled trial, and COMFORT-
II was an open-label trial comparing ruxolitinib with the
best available therapy. In both trials, ruxolitinib was su-
perior to control interventions, reducing spleen size and
improving MF-related symptoms and quality-of-life
(QoL) measures. Spleen volume reductions and im-
provements in measures of QoL at week 24 in
COMFORT-I were observed regardless of MF subtype,
age, International Prognostic Scoring System (IPSS) risk
score, Eastern Cooperative Oncology Group (ECOG)
performance status, and baseline hemoglobin level,
platelet count, spleen size, and JAK2V617F mutation
status [14].
Long-term follow-up analyses of the COMFORT
studies have indicated durable clinical benefit and are
suggestive of a survival advantage with ruxolitinib treat-
ment [15–17]. Most nonhematologic adverse events in
COMFORT-I and COMFORT-II were grade 1 or 2, with
the rate generally decreasing with long-term ruxolitinib
treatment [15, 16]. Dose-dependent cytopenias were the
most common hematologic adverse events. These oc-
curred primarily within the first 12 weeks of ruxolitinib
treatment and stabilized thereafter in patients continuing
therapy, with hemoglobin levels returning to near-
baseline levels [15, 16].
This analysis reports the final long-term efficacy and
safety results of COMFORT-I after 5 years of ruxolitinib
treatment.
Methods
Study design and patients
The detailed study design and protocol of the randomized,
double-blind, placebo-controlled, phase 3 COMFORT-I
trial have been reported previously [12]. The study was
conducted in 89 sites across Australia, Canada, and the
USA. Briefly, patients with intermediate-2 or high-risk MF
and splenomegaly of >5 cm below the left costal margin
by palpation were eligible.
The protocol was reviewed and approved by each par-
ticipating site’s institutional review board. All patients
provided written informed consent.
Randomization and masking
Patients were randomized 1:1 to ruxolitinib or match-
ing placebo tablets by a centralized interactive voice
response system (IVRS). Study investigators and pa-
tients were blinded to the treatment. Study treatments
were provided in encoded bottles, and patient study
drug assignments were provided to site staff by the
IVRS.
Procedures
Study treatments, administered orally twice daily, were
ruxolitinib (Incyte Corporation, Wilmington, DE; dosing
based on baseline platelet counts: 100–200 × 109/L,
15 mg; >200 × 109/L, 20 mg) or placebo. Dose modifica-
tion was allowed for efficacy and safety. Crossover from
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placebo to ruxolitinib was permitted before week 24 for
protocol-defined worsening splenomegaly. After week
24, patients with protocol-defined worsening symptom-
atic spleen growth either received unblinded ruxolitinib
or discontinued the study; patients with protocol-
defined asymptomatic spleen growth were given the op-
tion to unblind, after which they were required to re-
ceive ruxolitinib or discontinue the study.
This final analysis occurred when all the patients
reached the 5-year visit or discontinued participation.
Changes from baseline or crossover baseline in spleen
volume were assessed by magnetic resonance imaging or
computed tomography every 12 weeks from weeks 12 to
72 and every 24 weeks thereafter. Patients who had a
spleen volume measurement at baseline and each time
point of interest were evaluable to determine if a ≥35%
reduction from baseline in spleen volume was achieved;
all patients who withdrew before the time point were
considered nonresponders.
Outcomes
The primary endpoint was the proportion of patients
who achieved spleen response (≥35% reduction from
baseline in spleen volume) at week 24. Secondary end-
points reported in this analysis included duration of
spleen response and overall survival (OS).
Hematologic adverse events were based on laboratory
abnormalities. Because the majority of the anemia and
thrombocytopenia events occurred early in the study,
the incidence of new-onset or worsening grade 3 or 4
anemia or thrombocytopenia was assessed at 6-month
intervals in patients originally randomized to ruxolitinib.
The placebo group was included in only the first 6-
month interval because all the patients receiving placebo
discontinued or crossed over to ruxolitinib within
3 months of the primary analysis. Nonhematologic ad-
verse events were assessed per National Cancer Institute
Common Terminology Criteria for Adverse Events [18].
The incidence of nonhematologic adverse events was
assessed in yearly intervals for patients originally ran-
domized to ruxolitinib.
Statistical analysis
Changes from baseline or crossover baseline in spleen
volume were summarized with descriptive statistics.
Durability of spleen response and OS were calculated
with the Kaplan-Meier method in the intent-to-treat
population. OS was calculated based on randomized
treatment. Spleen response was considered lost at the
first measurement that was no longer a ≥35% reduction
from baseline and was also a >25% increase from the
nadir. Hazard ratio with 95% confidence interval and P
values were calculated with the Cox proportional haz-
ards model and the log-rank test. A subgroup analysis of
OS was conducted in patients with intermediate-2 or
high-risk MF per IPSS criteria [19].
Safety analyses were conducted in all patients who re-
ceived ≥1 dose of study treatment. The incidence of
new-onset or worsening grade ≥3 anemia and
thrombocytopenia (based on laboratory data) and of
new-onset or worsening all-grade and grade ≥3 nonhe-
matologic adverse events was calculated using the life-
table method. The time to the first event censored at the
date of the last laboratory evaluation was used for
anemia and thrombocytopenia; the earlier discontinu-
ation or date of data cutoff was used for nonhematologic
adverse events. Per the life-table method, the incidence
of each adverse event was based on the effective sample
size of the time interval, which was the number of pa-
tients at risk at the beginning of the interval minus half
of the censored patients during the time interval.
Statistical analyses were conducted using SAS version
9.2 (SAS Institute, Cary, NC).
The trial was overseen by a data monitoring committee
and is registered at ClinicalTrials.gov (NCT00952289).
Role of the funding source
Conduct of this study and editorial assistance were
funded by Incyte Corporation. Incyte Corporation em-
ployees worked with external investigators in designing
the study, analyzing data, and confirming accuracy of
this report. The authors had full access to all the data in




Patients were recruited between September 2009 and
April 2010 and randomized to ruxolitinib (n = 155) or
placebo (n = 154; Fig. 1). All patients were included in
the intent-to-treat population; three patients in the pla-
cebo group were not evaluable for safety. By the time of
the 3-year analysis, all evaluable patients in the placebo
group had discontinued (40/151 [26.5%]) or crossed over
to ruxolitinib (111/151 [73.5%]) [15]. The median
(range) time to crossover was 39.9 (5.0–65.3) weeks. At
study termination (i.e., the 5-year data cutoff ), 27.7%
(43/155) of patients originally randomized to ruxolitinib
and 25.2% (28/111) of those who crossed over to ruxoli-
tinib were receiving treatment in the study. An add-
itional four patients in the ruxolitinib-randomized group




Among patients originally randomized to ruxolitinib,
59.4% (92/155) had achieved a ≥35% reduction in spleen
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volume at any time during the study, with a median dur-
ation of response of 168.3 weeks (Fig. 2). The proportion
of evaluable patients (i.e., those with measurements at
baseline and each time point) in the ruxolitinib-
randomized group who had a ≥35% reduction from
baseline in spleen volume (including patients who had
withdrawn as nonresponders) was 41.9% (65/155) at
week 24, 36.6% (52/142) at week 48, 34.9% (52/149) at
week 96, 28.5% (41/144) at week 144, 22.6% (33/146)
at week 192, 20.1% (30/149) at week 240, and 18.5%
(27/146) at week 264. Among patients continuing
treatment with ruxolitinib, median percentage reduc-
tions from baseline in spleen volume were rapid and
durable. In the ruxolitinib-randomized group, the median
(range) percentage changes from baseline were −33.0%
(−75.9 to 25.1%) and −40.8% (−95.9 to 73.3%) at 24 and
240 weeks, respectively; the median (range) percentage
changes from crossover baseline were −37.3% (−64.8 to
26.0%) and −75.7% (−85.8 to 49.1%) in the ruxolitinib
crossover group (Fig. 3), although the number of evaluable
patients was limited at 240 weeks (n = 9).
Overall survival
At the time of the final 5-year analysis, median follow-
up time for the OS analysis was 268.4 weeks for the rux-
olitinib group and 269.0 weeks for the placebo group.
Patients randomized to ruxolitinib experienced pro-
longed OS compared with those in the placebo group.
Fig. 1 Patient disposition. *Three patients in the placebo group were not evaluable for safety (n = 151); these patients were excluded from the
calculation of the percentage of patients who discontinued. (dagger) Limited to patients whose study discontinuation dates matched their dates
of death. (double dagger) Including but not limited to the following: received a different therapy, transitioned to commercial ruxolitinib, and loss
of response
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Median OS was not reached in the ruxolitinib-
randomized group. Among patients randomized to
placebo, median OS was 108 weeks for patients censored
at crossover and 200 weeks for all patients (HR, 0.69;
95% CI, 0.50–0.96; P = 0.025; Fig. 4). There were a total
of 69 deaths (regardless of cause) in the ruxolitinib-
randomized group and 82 deaths among those random-
ized to placebo. In a subgroup analysis by IPSS risk sta-
tus, there was a nonsignificant trend toward longer OS
among patients in the ruxolitinib group compared with
the placebo group for both intermediate-2 and high-risk
patients (Fig. 5).
Safety
The median (range) ruxolitinib exposure duration was
149.3 (4.3–296.0) weeks in the ruxolitinib-randomized
group and 111.0 (0.9–256.1) weeks in the ruxolitinib
crossover group. The median (range) duration of expos-
ure to placebo was 37.1 (3.6–65.3) weeks. Among
patients who remained on treatment until study termin-
ation, the ruxolitinib exposure duration was 265.4
(249.9–296.0) weeks for the 43 patients in the group
randomized to ruxolitinib and 229.6 (200.1–256.1) weeks
for the 28 patients in the ruxolitinib crossover group.
Ruxolitinib exposure was more than 1 to 2 years for
23/155 (14.8%) and 15/111 (13.5%) patients in the
ruxolitinib-randomized group and the ruxolitinib cross-
over group, respectively; more than 2 to 3 years for
22/155 (14.2%) and 16/111 (14.4%) patients; more
than 3 to 4 years for 19/155 (12.3%) and 11/111
(9.9%) patients; and more than 4 years for 62/155
(40.0%) and 35/111 (31.5%) patients.
Fig. 2 Duration of ≥35% reduction from baseline in spleen volume. Duration of spleen response was evaluated for the 92 patients in the
ruxolitinib group who achieved a ≥35% reduction from baseline in spleen volume. NE, not evaluable
Fig. 3 Median percentage change from baseline in spleen volume over time. *For patients in the ruxolitinib crossover group, baseline represents
the date of crossover to ruxolitinib. BL, baseline
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Fig. 4 Overall survival. The overall survival analysis included all patients who died during the study or during long-term follow-up after discontinuation
of study treatment. HR, hazard ratio
Fig. 5 Overall survival by IPSS risk status. In both treatment arms, overall survival was significantly longer for patients with int-2 compared with
high-risk MF at diagnosis (ruxolitinib, P = 0.002; placebo, P = 0.004). Ruxolitinib was associated with nonsignificant survival advantages compared
with placebo for both the int-2 and high-risk patient subgroups. HR, hazard ratio; int-2, intermediate-2; IPSS, International Prognostic Scoring
System; MF, myelofibrosis
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The incidence of new-onset nonhematologic adverse
events generally stabilized or decreased with long-term
treatment in the ruxolitinib-randomized group (Tables 1
and 2). The most common new-onset all-grade nonhe-
matologic adverse events starting ≥48 months after
ruxolitinib initiation were fatigue (33.3%), pneumonia
(16.4%), constipation (16.0%), cough (15.4%), and head-
ache (15.4%); the most common grade 3 or 4 adverse
events were pneumonia (15.6%), congestive cardiac failure
(6.2%), sepsis (6.2%), and squamous cell carcinoma (6.2%).
Anemia and thrombocytopenia (per abnormal hema-
tologic laboratory values) occurred in most patients in
the ruxolitinib-randomized group (98.7 and 83.9%,
respectively). The rates of new or worsening grade 3 or
4 anemia, thrombocytopenia, and leukopenia were the
highest within the first 6 months of treatment, decreasing
thereafter (Fig. 6). No patients in the ruxolitinib-
randomized group had new or worsening grade 3 or 4
anemia, thrombocytopenia, or leukopenia after month 42.
In agreement with the hematologic laboratory abnormal-
ities over time in the ruxolitinib-randomized group, mean
hemoglobin levels decreased during the first 12 weeks of
treatment with randomized or crossover ruxolitinib but
increased toward baseline levels and stabilized thereafter
(Fig. 7). Similarly, mean platelet and white blood cell
counts also decreased during the first 12 weeks of treat-
ment with ruxolitinib, after which they remained stable
(Fig. 7). In agreement with these blood count dynamics,
the mean (SD) number of transfusions per month in the
ruxolitinib group peaked between weeks 4 and 8 (1.2
[1.75]) then decreased steadily until weeks 36 to 48 (0.7
[1.35]), stabilizing thereafter.
Table 1 Incidence of new-onset all-grade nonhematologic adverse events in the ruxolitinib group regardless of causality, grouped
by treatment time interval
Ruxolitinib (n = 155)
0– < 12 Months 12– < 24 Months 24– < 36 Months 36– < 48 Months ≥48 Months
Event,*n/N (%)
Fatigue 43/148.5 (29.0) 14/92.0 (15.2) 10/65.5 (15.3) 5/45.0 (11.1) 7/21.0 (33.3)
Diarrhea 41/147.5 (27.8) 6/89.0 (6.7) 7/65.0 (10.8) 5/46.5 (10.8) 3/20.5 (14.6)
Ecchymosis 31/146.0 (21.2) 10/96.0 (10.4) 4/70.0 (5.7) 1/55.0 (1.8) 1/25.0 (4.0)
Dyspnea 28/146.0 (19.2) 10/98.5 (10.2) 2/70.0 (2.9) 2/54.5 (3.7) 3/25.0 (12.0)
Dizziness 26/144.0 (18.1) 10/96.0 (10.4) 2/66.5 (3.0) 1/49.5 (2.0) 1/21.5 (4.7)
Pain in extremity 26/144.5 (18.0) 6/97.0 (6.2) 3/71.0 (4.2) 2/51.5 (3.9) 1/21.5 (4.7)
Peripheral edema 26/145.5 (17.9) 7/99.5 (7.0) 8/75.0 (10.7) 3/53.5 (5.6) 2/23.0 (8.7)
Headache 24/144.5 (16.6) 5/99.0 (5.1) 3/75.0 (4.0) 4/58.0 (6.9) 4/26.0 (15.4)
Nausea 24/144.5 (16.6) 7/102.5 (6.8) 4/79.0 (5.1) 5/61.0 (8.2) 4/27.5 (14.5)
Constipation 21/145.0 (14.5) 10/105.0 (9.5) 8/78.5 (10.2) 4/56.5 (7.1) 4/25.0 (16.0)
Abdominal pain 20/144.5 (13.8) 6/106.0 (5.7) 3/84.0 (3.6) 4/66.0 (6.1) 4/29.5 (13.6)
Insomnia 20/144.5 (13.8) 7/104.5 (6.7) 3/80.0 (3.8) 1/62.5 (1.6) 1/28.0 (3.6)
Vomiting 20/145.5 (13.7) 3/105.5 (2.8) 2/82.5 (2.4) 4/64.5 (6.2) 4/29.0 (13.8)
Pyrexia 20/148.0 (13.5) 8/109.5 (7.3) 7/82.5 (8.5) 3/62.0 (4.8) 2/27.5 (7.3)
Cough 19/145.0 (13.1) 14/105.5 (13.3) 3/74.5 (4.0) 4/58.5 (6.8) 4/26.0 (15.4)
Arthralgia 17/144.0 (11.8) 6/103.0 (5.8) 6/75.5 (7.9) 6/53.5 (11.2) 3/21.5 (14.0)
Muscle spasms 14/143.0 (9.8) 3/105.0 (2.9) 7/81.0 (8.6) 6/58.0 (10.3) 1/23.0 (4.3)
Back pain 13/143.0 (9.1) 11/106.5 (10.3) 0 4/58.0 (6.9) 3/25.5 (11.8)
Night sweats 13/143.0 (9.1) 3/105.5 (2.8) 3/81.5 (3.7) 1/61.5 (1.6) 4/28.0 (14.3)
Pneumonia 13/145.0 (9.0) 7/110.0 (6.4) 3/82.5 (3.6) 3/65.0 (4.6) 5/30.5 (16.4)
Upper respiratory tract infection 11/143.0 (7.7) 12/108.0 (11.1) 4/74.5 (5.4) 4/55.0 (7.3) 3/24.0 (12.5)
Fall 7/143.5 (4.9) 2/111.5 (1.8) 1/87.0 (1.1) 3/68.5 (4.4) 4/30.5 (13.1)
Musculoskeletal pain 7/143.0 (4.9) 5/112.0 (4.5) 7/85.5 (8.2) 2/62.5 (3.2) 4/29.0 (13.8)
Pruritus 7/142.5 (4.9) 8/110.5 (7.2) 1/81.0 (1.2) 1/63.5 (1.6) 3/29.0 (10.3)
Herpes zoster 3/143.5 (2.1) 4/115.5 (3.5) 3/87.5 (3.4) 3/66.0 (4.5) 3/29.0 (10.3)
Squamous cell carcinoma 0 1/116.5 (0.9) 2/91.5 (2.2) 2/70.5 (2.8) 4/32.0 (12.5)
*Occurring in >10% of patients in the ruxolitinib group in ≥1 yearly interval
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Serious adverse events occurred at any time during
treatment with ruxolitinib in 103/155 (66.5%) patients in
the ruxolitinib-randomized group and 74/111 (66.7%)
patients in the ruxolitinib crossover group. The most
frequent serious adverse events, occurring in ≥4% of pa-
tients in the ruxolitinib-randomized or crossover groups,
were pneumonia (randomized, 15.5%; crossover, 10.8%),
anemia (11.0%; 11.7%), sepsis (4.5%; 3.6%), and congest-
ive cardiac failure (3.2%; 4.5%).
Throughout the course of the study, adverse events re-
sulted in a ruxolitinib dose decrease in 88/155 (56.8%)
patients in the ruxolitinib-randomized group and 45/111
(40.5%) patients in the ruxolitinib crossover group.
Thrombocytopenia was the most frequent cause of dose
decreases, occurring in 75/155 (48.4%) and 36/111
(32.4%) patients in the ruxolitinib-randomized and
crossover groups, respectively.
Adverse events resulted in discontinuation of treat-
ment in 50/155 (32.3%) patients originally randomized
to ruxolitinib, 39/111 (35.1%) in the ruxolitinib crossover
group, and 19/151 (12.6%) during treatment with pla-
cebo. The most common reasons, occurring in ≥2.0% of
patients treated with ruxolitinib, were disease progres-
sion (3.2%), acute myeloid leukemia (AML; 2.6%), and
anemia (2.6%) in the ruxolitinib-randomized group, and
thrombocytopenia (3.6%) and AML (3.6%) in the ruxoli-
tinib crossover group.
Herpes zoster infections occurred at higher rates in
patients treated with ruxolitinib compared with placebo
(Table 3). All herpes zoster events in the ruxolitinib-
Table 2 Incidence of new-onset grade 3 or 4 nonhematologic adverse events in the ruxolitinib group regardless of causality,
grouped by treatment time interval
Ruxolitinib (n = 155)
0– < 12 Months 12– < 24 Months 24– < 36 Months 36– < 48 Months ≥48 Months
Event,*n/N (%)
Fatigue 9/144.5 (6.2) 1/113.0 (0.9) 3/90.0 (3.3) 1/69.5 (1.4) 0
Pneumonia 8/144.0 (5.6) 4/112.0 (3.6) 3/86.0 (3.5) 2/67.5 (3.0) 5/32.0 (15.6)
Abdominal pain 6/143.5 (4.2) 0 3/93.5 (3.2) 1/72.5 (1.4) 1/32.0 (3.1)
Arthralgia 3/142.5 (2.1) 0 0 1/70.0 (1.4) 0
Diarrhea 3/143.5 (2.1) 0 0 1/72.5 (1.4) 0
Dyspnea 3/143.5 (2.1) 1/116.5 (0.9) 2/92.5 (2.2) 1/71.5 (1.4) 1/31.5 (3.2)
Pain in extremity 3/142.5 (2.1) 0 1/89.5 (1.1) 1/69.5 (1.4) 1/30.5 (3.3)
Acute myeloid leukemia 2/143.5 (1.4) 0 1/93.0 (1.1) 2/74.0 (2.7) 0
Fall 2/142.5 (1.4) 1/114.5 (0.9) 0 2/71.0 (2.8) 1/30.5 (3.3)
Gastrointestinal hemorrhage 2/142.5 (1.4) 1/115.0 (0.9) 0 0 0
Hyperuricemia 2/142.5 (1.4) 1/114.5 (0.9) 0 1/71.5 (1.4) 0
Hypoxia 2/142.5 (1.4) 0 2/92.0 (2.2) 0 1/31.5 (3.2)
Muscular weakness 2/143.0 (1.4) 0 1/91.5 (1.1) 0 0
Septic shock 2/143.5 (1.4) 0 0 0 0
Acute renal failure 1/142.5 (0.7) 1/116.0 (0.9) 3/93.0 (3.2) 2/72.5 (2.8) 1/31.5 (3.2)
Back pain 1/142.5 (0.7) 2/116.0 (1.7) 0 0 0
Congestive cardiac failure 1/142.5 (0.7) 0 1/92.0 (1.1) 0 2/32.5 (6.2)
Epistaxis 1/143.0 (0.7) 2/117.0 (1.7) 0 0 0
Sepsis 1/143.0 (0.7) 2/116.5 (1.7) 2/92.5 (2.2) 1/73.0 (1.4) 2/32.5 (6.2)
Upper abdominal pain 1/143.0 (0.7) 0 2/92.5 (2.2) 0 0
Cellulitis 0 0 0 2/73.5 (2.7) 0
Myocardial infarction 0 1/117.0 (0.9) 0 2/73.5 (2.7) 0
Osteoarthritis 0 0 1/92.5 (1.1) 0 2/32.5 (6.2)
Osteomyelitis 0 0 0 2/73.0 (2.7) 0
Squamous cell carcinoma 0 1/116.5 (0.9) 0 0 2/32.5 (6.2)
Urinary tract infection 0 1/116.5 (0.9) 1/92.0 (1.1) 0 2/33.0 (6.1)
Wound infection 0 0 0 0 2/33.0 (6.1)
*Occurring in ≥2 patients in the ruxolitinib group in any yearly interval
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randomized group were grade 1 or 2, occurring in three
or four patients each year. Among all patients treated
with ruxolitinib, the majority of cases were single epi-
sodes that were grade 2 or lower and resolved without
long-term sequelae. The only serious event of herpes
zoster infection occurred in a patient randomized to pla-
cebo after crossing over to ruxolitinib.
Sepsis occurred at similar rates between patients
treated with ruxolitinib and those receiving placebo
(Table 3). All sepsis events were grade 3 or 4, with the
exception of one grade 2 event in the placebo group.
Serious events of sepsis and septic shock occurred at
rates of 1.5 and 0.4 per 100 patient-years of exposure in
the ruxolitinib-randomized group and 1.5 each in the
ruxolitinib crossover group.
Nonmelanoma skin cancers, including basal cell car-
cinoma and squamous cell carcinoma of the skin, oc-
curred at similar rates between patients treated with
ruxolitinib and those receiving placebo (Table 3). Basal
cell carcinoma occurred at a rate of 2.7 per 100 patient-
years of exposure in the ruxolitinib-randomized group,
4.0 in the ruxolitinib crossover group, and 3.9 among
patients during treatment with placebo (Table 3). There
were two cases of basal cell carcinoma in the ruxolitinib
crossover group; in both cases, patients had a history of
skin cancer.
Fig. 6 Incidence of new or worsening grade 3 or 4 a anemia, b
thrombocytopenia, and c leukopenia over time. Anemia,
thrombocytopenia, and leukopenia were based on hematologic
laboratory abnormalities. (asterisk) Placebo arm data are only shown
up to 6 months because all patients randomized to placebo crossed
over or discontinued within 3 months of the primary analysis
Fig. 7 Mean blood counts over time in the ruxolitinib randomized
and ruxolitinib crossover groups. Blood counts were based on
measurements of a hemoglobin level, b platelet counts, and c white
blood cell counts. *For patients in the ruxolitinib crossover group, BL
represents the date of crossover to ruxolitinib. BL, baseline
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Disease transformation to AML occurred in five pa-
tients each in the ruxolitinib-randomized and ruxoliti-
nib crossover groups; no patients developed AML
during treatment with placebo (Table 3). Overall,
AML occurred in five male and five female patients.
The median (range) time from the first ruxolitinib
dose to AML diagnosis was 838 (157–1150) days in
the ruxolitinib-randomized group and 376 (21–666)
days in the ruxolitinib crossover group; median
(range) time from MF diagnosis to AML diagnosis
was 1190 (699–1708) days and 1015 (372–11,971)
days, respectively. Prior medications for the treatment
of MF in patients who developed AML were
hydroxyurea (ruxolitinib-randomized group, n = 2;
ruxolitinib crossover group, n = 2) and lenalidomide,
and corticosteroids (all in one patient in the ruxoliti-
nib crossover group); three patients in the ruxolitinib-
randomized group and two in the ruxolitinib cross-
over group had no prior treatments for MF.
Overall, 28/155 (18.1%) patients in the ruxolitinib-
randomized group and 39/151 (25.8%) in the placebo
randomized group experienced a treatment-emergent
adverse event that resulted in death while on study or
within 28 days of the last dose of study drug. Among the
patients randomized to placebo, a treatment-emergent
adverse event led to death in 11/151 (7.3%) patients
Table 3 Exposure-adjusted rates of select adverse events







All grade Grade 3 or 4 All grade Grade 3 or 4 All grade Grade 3 or 4
Event, n/PYE (rate per 100 PYE)
Infections and infestationsa
Upper respiratory tract infection 34/398.0 (8.5) 0 22/230.5 (9.5) 0 15/96.9 (15.5) 1/96.9 (1.0)
Urinary tract infection 31/414.3 (7.5) 4/414.3 (1.0) 16/240.5 (6.7) 3/240.5 (1.2) 7/101.3 (6.9) 1/101.3 (1.0)
Pneumonia 31/432.3 (7.2) 22/432.3 (5.1) 18/253.6 (7.1) 8/253.6 (3.2) 11/102.4 (10.7) 8/102.4 (7.8)
Herpes zoster 16/452.5 (3.5) 0 14/241.2 (5.8) 1/242.2 (0.4) 1/104.1 (1.0) 0
Bronchitis 14/450.5 (3.1) 0 11/244.9 (4.5) 3/244.9 (1.2) 2/104.2 (1.9) 0
Nasopharyngitis 14/449.1 (3.1) 0 9/253.6 (3.5) 0 9/98.4 (9.1) 0
Sinusitis 12/453.2 (2.6) 1/453.2 (0.2) 7/252.3 (2.8) 0 3/102.7 (2.9) 1/102.7 (1.0)
Cellulitis 10/467.8 (2.1) 2/467.8 (0.4) 3/262.6 (1.1) 0 2/103.5 (1.9) 0
Influenza 8/469.0 (1.7) 0 3/266.0 (1.1) 1/266.0 (0.4) 0 0
Sepsis 8/480.3 (1.7) 8/480.3 (1.7) 4/267.4 (1.5) 4/267.4 (1.5) 2/104.0 (1.9) 1/104.0 (1.0)
Tooth abscess 7/476.3 (1.5) 1/476.3 (0.2) 4/261.3 (1.5) 0 0 0
Oral herpes 6/469.8 (1.3) 0 2/269.1 (0.7) 0 2/103.2 (1.9) 0
Skin infection 5/469.8 (1.1) 0 3/269.5 (1.1) 0 1/104.4 (1.0) 0
Viral infection 5/471.2 (1.1) 0 2/265.4 (0.8) 0 0 0
Viral gastroenteritis 4/470.6 (0.9) 0 1/270.1 (0.4) 0 2/103.5 (1.9) 0
Diverticulitis 4/475.0 (0.8) 1/475.0 (0.2) 3/268.5 (1.1) 1/268.5 (0.4) 2/103.6 (1.9) 0
Ear infection 4/473.3 (0.8) 0 4/267.8 (1.5) 0 0 0
Fungal infection 4/479.4 (0.8) 0 2/267.6 (0.7) 1/267.6 (0.4) 2/103.8 (1.9) 0
Localized infection 4/479.1 (0.8) 0 1/269.2 (0.4) 1/269.2 (0.4) 1/104.1 (1.0) 0
Lower respiratory tract infection 4/476.9 (0.8) 0 1/270.5 (0.4) 0 2/103.3 (1.9) 1/103.3 (1.0)
Septic shock 2/484.6 (0.4) 2/484.6 (0.4) 3/270.5 (1.1) 3/270.5 (1.1) 0 0
Neoplasms
Basal cell carcinoma 12/450.9 (2.7) 2/450.9 (0.4) 10/252.7 (4.0) 2/252.7 (0.8) 4/103.7 (3.9) 0
Squamous cell carcinoma 10/462.6 (2.2) 2/462.6 (0.8) 10/252.0 (4.0) 3/252.0 (1.2) 4/102.9 (3.9) 0
Squamous cell carcinoma of the skin 9/470.2 (1.9) 3/470.2 (0.6) 3/266.4 (1.1) 1/266.4 (0.4) 1/104.7 (1.0) 0
Acute myeloid leukemia 5/483.8 (1.0) 5/483.8 (1.0) 5/270.1 (1.9) 5/270.1 (1.9) 0 0
PYE, patient-years of exposure
*Adverse events that occurred following the first dose of ruxolitinib (ie, after crossover from placebo) were included in the ruxolitinib crossover group
aOccurring in ≥5 patients treated with ruxolitinib
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during treatment with placebo and 28/111 (25.2%) pa-
tients after crossover to ruxolitinib (Table 4).
Discussion
This final analysis of the COMFORT-I trial demon-
strated that treatment with ruxolitinib was associated
with rapid and durable reductions in splenomegaly and
significantly longer OS compared with patients originally
randomized to placebo. Patient risk of death was ap-
proximately 30% lower in the ruxolitinib group com-
pared with placebo, despite the crossover from placebo
to ruxolitinib. Given that COMFORT-I was restricted to
patients with intermediate-2 or high-risk MF with
splenomegaly, OS data suggest that delaying treatment
with ruxolitinib may worsen outcomes and that studies
evaluating ruxolitinib in patients with earlier MF disease
states may be warranted.
The exact mechanism by which ruxolitinib prolongs
survival and ameliorates splenomegaly remains unclear,
but it is rational to hypothesize that the downstream ef-
fects of ruxolitinib confer changes in cytokines, meta-
bolic properties, and JAK2V617F allele burden that may
play a role. Ruxolitinib has been associated with reduc-
tions in inflammatory cytokines and markers of inflam-
mation [12], improvements in measures of metabolic
and nutrition status [20], reduced fibrosis in some pa-
tients [17], and reductions in JAK2V617F allele burden
[21]. In COMFORT-I patients receiving long-term treat-
ment with ruxolitinib, relationships have been identified
between reductions in spleen volume and (1) increases
in body weight and normalization of serum albumin and
total cholesterol levels [20] and (2) reductions in
JAK2V617F allele burden in some patients [21]. In
addition, ruxolitinib has been associated with improve-
ments in spleen volume and OS in a wide variety of
patient subgroups stratified by MF subtype, age, IPSS
risk score, ECOG performance status, and baseline
hemoglobin level, platelet count, spleen size, and
JAK2V617F mutation status [14]. Future work will be re-
quired to elucidate the mechanism by which ruxolitinib
is efficacious and if there are any related disease markers
or patient characteristics that could be helpful in identi-
fying the types of patients who may benefit the most
from ruxolitinib treatment.
Overall, the safety profile was supportive of long-term
treatment with ruxolitinib, with no unexpected safety
signals. The nonhematologic adverse event rates gener-
ally remained stable or decreased with prolonged ruxoli-
tinib treatment duration and were consistent with those
reported in previous analyses of the COMFORT-I study
[12, 15]. As expected, based on the mechanism of action
of ruxolitinib as a JAK1/JAK2 inhibitor [22, 23],
thrombocytopenia and anemia occurred in most patients
treated with ruxolitinib. Anemia and thrombocytopenia
can be managed with dose adjustments and, for some
patients with anemia, red blood cell transfusions [24].
Indeed, although thrombocytopenia was the most com-
mon cause for ruxolitinib dose reduction in COMFORT-I,
thrombocytopenia and anemia resulted in relatively
few discontinuations (each ≤3.6% in the ruxolitinib-
Table 4 Treatment-emergent adverse events resulting in death*









Death caused by any treatment-
emergent adverse event
28 (18.1) 28 (25.2) 11 (7.3)
Sepsis 4 (2.6) 2 (1.8) 1 (0.7)
Disease progression 3 (1.9) 4 (3.6) 3 (2.0)
Pneumonia 3 (1.9) 1 (0.9) 1 (0.7)
Acute myeloid leukemia 2 (1.3) 3 (2.7) 0
Cerebral hemorrhage 2 (1.3) 1 (0.9) 1 (0.7)
Septic shock 2 (1.3) 2 (1.8) 0
Acute renal failure 1 (0.6) 1 (0.9) 0
Anemia 1 (0.6) 0 0
Cardiac arrest 1 (0.6) 0 0
Death, unspecified 1 (0.6) 1 (0.9) 0
Falling injury 1 (0.6) 0 0
Hemorrhagic shock 1 (0.6) 1 (0.9) 0
Metastatic NSCLC 1 (0.6) 0 0
Multiorgan failure 1 (0.6) 0 1 (0.7)
Muscular weakness 1 (0.6) 0 0
Myocardial infarction 1 (0.6) 1 (0.9) 0
Pancreatic carcinoma 1 (0.6) 0 0
Renal failure 1 (0.6) 0 0
Respiratory failure 1 (0.6) 0 0
Splenic infarction 1 (0.6) 0 0
Congestive cardiac failure 0 2 (1.8) 0
Myelofibrosis 0 2 (1.8) 1 (0.7)
Cardiac failure 0 1 (0.9) 0
Pneumonia aspiration 0 2 (1.8) 0
Anastomotic hemorrhage 0 1 (0.9) 0
Cholecystitis 0 1 (0.9) 0
Delirium 0 1 (0.9) 0
Road traffic accident 0 1 (0.9) 0
Splenic rupture 0 1 (0.9) 0
Suicide 0 1 (0.9) 0
Gastrointestinal hemorrhage 0 0 1 (0.7)
Intestinal perforation 0 0 1 (0.7)
Staphylococcal infection 0 0 1 (0.7)
NSCLC, non-small cell lung cancer
*Limited to fatal treatment-emergent adverse events occurring during
treatment with study drug or within 28 days of the last dose of study drug
aPatient deaths were counted once under each Medical Dictionary for
Regulatory Activities system organ class and preferred term, and therefore
individual patients may have had >1 cause of death
bFatal treatment-emergent adverse events that occurred following the first
dose of ruxolitinib (ie, after crossover from placebo) were included in the
ruxolitinib crossover group
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randomized and crossover groups). Mean hemoglobin,
platelet, and white blood cell levels stabilized after
12 weeks of treatment, with hemoglobin levels return-
ing to near-baseline levels thereafter; however, this
finding must be interpreted taking into account the
positive selection of patients remaining on study.
Mean blood transfusion rates were in agreement with
these trends. Nevertheless, ruxolitinib may provide a
survival benefit even in the presence of anemia. In a
pooled analysis of COMFORT-I and COMFORT-II 3-
year data, treatment with ruxolitinib was associated
with a survival advantage regardless of anemia at
baseline (3-year OS probability: ruxolitinib, 0.66; con-
trol, 0.57) or after initiating study treatment (3-year
OS probability: ruxolitinib, 0.87; control, 0.66) [25].
Herpes zoster infections occurred at higher rates
among patients treated with ruxolitinib compared with
placebo. The incidence of herpes zoster infections in-
creased with longer exposure to ruxolitinib (0–12 months’
exposure, 2.1%; ≥48 months’ exposure, 10.3%). However,
all but one case was grade 1 or 2, and it is unclear if this
increase was clinically relevant. Other infections, including
pneumonia, sepsis, upper respiratory tract infection, and
urinary tract infection, occurred at similar or lower rates
with ruxolitinib compared with placebo; however, pneu-
monia was the most common new-onset grade 3 or 4 ad-
verse event observed after 48 months of treatment with
ruxolitinib. Nonmelanoma skin cancers were observed in
patients treated with ruxolitinib; however, these occurred
at rates that were similar to or lower than those observed
during treatment with placebo. Finally, the incidence of
AML transformation in the ruxolitinib-randomized and
crossover groups was consistent with previous reports in
patients with MF [26, 27]. Although no patients developed
AML during treatment with placebo, the median exposure
(37.1 weeks) may not have been long enough to observe
AML transformations considering that the median time
from the first ruxolitinib dose to AML diagnosis was
119.7 weeks in the ruxolitinib-randomized group.
Overall, 48.9% of the COMFORT-I patient population
had died by the time of the final 5-year analysis. Causes
of death were generally consistent with expected mor-
bidities resulting from MF progression and/or other
underlying disease processes (e.g., infections, transform-
ation to AML), particularly in elderly and chronically ill
patients. The most common adverse events leading to
death in COMFORT-I were sepsis or septic shock,
followed by disease progression, pneumonia, and trans-
formation to AML. Eleven patients treated with ruxoliti-
nib died because of a cardiovascular, thrombotic, or
hemorrhagic event. In comparison, an international
retrospective analysis of 1131 patients with PMF en-
rolled between 1980 and 2007 reported that the leading
causes of death were transformation to AML, disease
progression, thrombosis and cardiovascular complica-
tions, and infection [19].
Conclusions
This final analysis of the COMFORT-I study included
5 years of treatment duration and demonstrated that
long-term ruxolitinib treatment in patients with
intermediate-2 or high-risk MF was associated with dur-
able reductions in spleen size and significantly longer
OS compared with placebo. The safety profile continued
to remain consistent with previous COMFORT-I and
COMFORT-II analysis [12, 13, 15–17], with no new or
unexpected adverse events identified with long-term
treatment. Collectively, these data and similar findings in
the 5-year analysis of the COMFORT-II study [17] sup-
port ruxolitinib as an effective long-term treatment op-
tion for patients with intermediate-2 or high-risk MF.
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